

## DAFTAR PUSTAKA

- Botros, M., & Sikaris, K.A. (2013). The De Ritis Ratio: The Test of Time. *Clin. Biochem. Rev.* 34 : 117.
- Cho, Y., Choi, J.W., Kwon, H., Kim, K.Y., Lee, B.C., Chu, H.H., *et al.* (2023). Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean liver cancer association. *Korean J. Radiol.* 24 : 606–625.
- Chu, H.H., Kim, J.H., Shim, J.H., Gwon, D.I., Ko, H.K., Shin, J.H., *et al.* (2021). Neutrophil-to-lymphocyte ratio as a biomarker predicting overall survival after chemoembolization for intermediate-stage hepatocellular carcinoma. *Cancers* 13 : 2830.
- Dahlan, M.S. (2016). Besar Sampel Dalam Penelitian Kedokteran Dan Kesehatan. Jakarta : Epidemiologi Indonesia.
- Deb, N., Lahon, D., & Sharma, P. (2016). A study on probable correlation of AST/ALT (De Ritis) ratio with the advancement of underlying severity of alcoholic liver disease in the North East Indian population. *Asian Pac. J. Health Sci.* 3 : 5–10.
- Ding, Z., Wang, L., Sun, J., Zheng, L., Tang, Y., & Tang, H. (2025). Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances. *Front. Oncol.* 15 : 1–16.
- Dorn, D.P., Bryant, M.K., Zarzour, J., Smith, J.K., Redden, D.T., Saddekni, S., *et al.* (2014). Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. *HPB* 16 : 648–655.
- El-Serag, H.B., & Rudolph, K.L. (2007). Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. *Gastroenterology* 132 : 2557–2576.
- Fadillah, M.A.M., Mashuri, Triawanti, Mulyani, N., & Rosida, A. (2022). Profil pasien karsinoma hepatoseluler yang menjalani terapi transarterial chemoembolization (TACE) di RSUD Ulin Banjarmasin periode 2016-2018. *Homeostasis* 5 : 19–28.
- Foglia, B., Turato, C., & Cannito, S. (2023). Hepatocellular carcinoma: latest research in pathogenesis, detection and treatment. *Int. J. Mol. Sci.* 24 : 12224.
- Ganesan, P., & Kulik, L.M. (2023). Hepatocellular carcinoma: new developments. *Clin. Liver Dis.* 27 : 85–102.
- Giannini, E., Risso, D., Botta, F., Chiarbonello, B., Fasoli, A., Malfatti, F., *et al.* (2003). Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. *Arch. Intern. Med.* 163 : 218–224.
- Granito, A., Facciorusso, A., Sacco, R., Bartalena, L., Mosconi, C., Cea, U.V., *et al.* (2021). TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. *J. Pers. Med.* 11 : 1041.

- Hasan, I., Gani, R.A., Sulaiman, A.S., Kurniawan, J., Lesmana, C.R.A., Jasirwan, C.O.M., *et al.* (2023). Profil Klinis dan Kesintasan Pasien Karsinoma Sel Hati di Rumah Sakit Rujukan Tersier Indonesia Tahun 2015-2021. *J. Penyakit Dalam Indones.* 10 : 9.
- Hsu, C.-Y., Lee, Y.-H., Hsia, C.-Y., Huang, Y.-H., Su, C.-W., Lin, H.-C., *et al.* (2013). Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. *Hepatology* 57 : 112–119.
- Hung, Y.-W., Lee, I.-C., Chi, C.-T., Lee, R.-C., Liu, C.-A., Chiu, N.-C., *et al.* (2021). Redefining tumor burden in patients with intermediate-stage hepatocellular carcinoma: the seven-eleven criteria. *Liver Cancer* 10 : 629–640.
- Huo, R.R., Pan, L.X., Wu, P.S., Liang, X.M., You, X.M., Ma, L., *et al.* (2024). Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy. *BJS Open* 8 : zrad155.
- Kamga Wouambo, R., Panka Tchinda, G., Kagoue Simeni, L.A., Djouela Djoulako, P.D., Yateu Wouambo, C.I., Tamko Mella, G.F., *et al.* (2023). Anti-hepatitis C antibody carriage and risk of liver impairment in rural-Cameroon: adapting the control of hepatocellular carcinoma for resource-limited settings. *BMC Infect. Dis.* 23 : 875.
- Kanda, T., & Yokosuka, O. (2015). The androgen receptor as an emerging target in hepatocellular carcinoma. *J. Hepatocell. Carcinoma* 2 : 91–99.
- Kemkes RI (2022). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1355/2022 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati pada Dewasa. Jakarta : Kementerian Kesehatan Republik Indonesia.
- Kim, D.Y. (2024). Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. *J. Liver Cancer* 24 : 62–70.
- Kohla, M.A.S., Abu Zeid, M.I., Al-Warraky, M., Taha, H., & Gish, R.G. (2015). Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. *BMJ Open Gastroenterol.* 2 : e000032.
- Kong, J.-Y., Li, Shu-Mei, Fan, H.-Y., Zhang, L., Zhao, H.-J., & Li, Sheng-Mian (2018). Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. *Medicine (Baltimore)* 97 : e11872.
- Kotsifa, E., Vergadis, C., Vailas, M., Machairas, N., Kykalos, S., Damaskos, C., *et al.* (2022). Transarterial chemoembolization for hepatocellular carcinoma: why, when, how? *J. Pers. Med.* 12 : 436.
- Kusnik, A., Penmetsa, A., Chaudhary, F., Renjith, K., Ramaraju, G., Laryea, M., *et al.* (2024). Clinical Overview of Sarcopenia, Frailty, and Malnutrition in Patients With Liver Cirrhosis. *Gastroenterol. Res.* 17 : 53–63.
- Lai, S.-W. (2019). Risk factors for hepatocellular carcinoma. *Cancer* 125 : 482.
- Liu, C., Jia, B.S., Zou, B.W., Du, H., Yan, L.N., Yang, J.Y., *et al.* (2017). Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios

- predict hepatocellular carcinoma prognosis after transarterial embolization. *Medicine (Baltimore)* 96 : e8512.
- Liu, H., Li, H., Deng, G., Zheng, X., Huang, Y., Chen, J., *et al.* (2024). Association of AST/ALT ratio with 90-day outcomes in patients with acute exacerbation of chronic liver disease: a prospective multicenter cohort study in China. *Front. Med.* 11 : 1307901.
- Llovet, J.M., & Lencioni, R. (2020). mRECIST for HCC: Performance and novel refinements. *J. Hepatol.* 72 : 288–306.
- Ma, W.-L., Lai, H.-C., Yeh, S., Cai, X., & Chang, C. (2014). Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. *Endocr. Relat. Cancer* 21 : R165–R182.
- Maulidia, V.N.R., Wardhani, P., & Setyoboedi, B. (2020). AST, ALT and albumin level in chronic hepatitis B patients with and without complications of cirrhosis and hepatocellular carcinoma. *Indones. J. Clin. Pathol. Med. Lab.* 26 : 344–349.
- McGlynn, K.A., Petrick, J.L., & El-Serag, H.B. (2021). Epidemiology of hepatocellular carcinoma. *Hepatology* 73 : 4–13.
- Miksad, R.A., Ogasawara, S., Xia, F., Fellous, M., & Piscaglia, F. (2019). Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. *BMC Cancer* 19.
- Mo, Q., Liu, Y., Zhou, Z., Li, R., Gong, W., Xiang, B., *et al.* (2022). Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy. *Front. Oncol.* 12 : 1–10.
- Pinheiro, P.S., Jones, P.D., Medina, H., Cranford, H.M., Koru-Sengul, T., Bungum, T., *et al.* (2024). Incidence of etiology-specific hepatocellular carcinoma: diverging trends and significant heterogeneity by race and ethnicity. *Clin. Gastroenterol. Hepatol.* 22 : 562–571.
- PN, A., Kholili, U., Maimunah, U., Setiawan, P.B., Nusi, I.A., Purbayu, H., *et al.* (2016). Response evaluation of patients undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma with respect to tumour size, number of lesion, and alpha-fetoprotein (AFP) level. *Indones. J. Gastroenterol. Hepatol. Dig. Endosc.* 17 : 3–9.
- PPHI (2021). Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta : Perhimpunan Peneliti Hati Indonesia.
- PPHI (2017). Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta : Perhimpunan Peneliti Hati Indonesia.
- Reig, M., Forner, A., Rimola, J., Ferrer-fàbrega, J., Burrel, M., Garcia-criado, Á., *et al.* (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J. Hepatol.* 76 : 681–693.
- Suresh, D., Srinivas, A.N., & Kumar, D.P. (2020). Etiology of hepatocellular carcinoma: special focus on fatty liver disease. *Front. Oncol.* 10 : 601710.
- Tümen, D., Heumann, P., Güllow, K., Demirci, C.N., Cosma, L.S., Müller, M., *et al.* (2022). Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. *Biomedicines* 10 : 3202.

- Villanueva, A. (2019). Hepatocellular carcinoma. *N. Engl. J. Med.* 380 : 1450–1462.
- Vitale, A., Farinati, F., Finotti, M., Renzo, C.D., Brancaccio, G., Piscaglia, F., *et al.* (2021). Overview of prognostic systems for hepatocellular carcinoma. *Cancers* 13 : 1673.
- Wang, F., Gao, S., Wu, M., Zhao, D., Sun, H., Yav, S., *et al.* (2023). The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE. *BMC Gastroenterol.* 23 : 80.
- Yen, Y.-H., Kee, K.-M., Li, W.-F., Liu, Y.-W., Wang, C.-C., Hu, T.-H., *et al.* (2023). Causes of death among patients with hepatocellular carcinoma according to chronic liver disease etiology. *Cancers* 15 : 1687.
- Zhang, L.X., Lv, Y., Xu, A.M., & Wang, H.Z. (2019). The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. *BMC Cancer* 19 : 841.
- Zhong, B.Y., Jin, Z.C., Chen, J.J., Zhu, H.D., & Zhu, X.L. (2023). Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. *J. Clin. Transl. Hepatol.* 11 : 480–489.